Scpharmaceuticals Inc (SCPH) Receives Consensus Rating of “Strong Buy” from Analysts

Scpharmaceuticals Inc (NASDAQ:SCPH) has been given an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.

Brokers have set a 1 year consensus price target of $12.67 for the company and are forecasting that the company will post ($0.58) EPS for the current quarter, according to Zacks. Zacks has also given Scpharmaceuticals an industry rank of 101 out of 255 based on the ratings given to its competitors.

Several analysts recently weighed in on SCPH shares. Zacks Investment Research upgraded Scpharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Leerink Swann cut their target price on Scpharmaceuticals from $20.00 to $12.00 and set an “outperform” rating on the stock in a research note on Thursday, June 14th. BMO Capital Markets cut their target price on Scpharmaceuticals from $24.00 to $14.00 and set an “outperform” rating on the stock in a research note on Thursday, June 14th. ValuEngine upgraded Scpharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Finally, Jefferies Financial Group cut their target price on Scpharmaceuticals from $26.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, June 14th.



Shares of SCPH stock traded up $0.01 on Friday, hitting $4.59. The stock had a trading volume of 52,710 shares, compared to its average volume of 48,005. The company has a debt-to-equity ratio of 0.10, a current ratio of 19.23 and a quick ratio of 19.23. The company has a market capitalization of $84.92 million and a P/E ratio of -0.57. Scpharmaceuticals has a one year low of $4.32 and a one year high of $18.17.

Hedge funds have recently modified their holdings of the company. California State Teachers Retirement System acquired a new position in shares of Scpharmaceuticals during the 1st quarter worth approximately $139,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Scpharmaceuticals during the 1st quarter worth approximately $167,000. Acadian Asset Management LLC acquired a new position in shares of Scpharmaceuticals during the 2nd quarter worth approximately $169,000. Bank of New York Mellon Corp acquired a new position in shares of Scpharmaceuticals during the 4th quarter worth approximately $414,000. Finally, Millennium Management LLC acquired a new position in shares of Scpharmaceuticals during the 4th quarter worth approximately $462,000. Institutional investors and hedge funds own 44.74% of the company’s stock.

Scpharmaceuticals Company Profile

scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.

Featured Story: How to Track your Portfolio in Google Finance

Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Leave a Reply